1 of 4
Veterinary vaccines are used for prevention of diseases that affect animals. Animal vaccination is a cost-effective solution to maintain animal health and sustainability, offering various benefits such as improved animal health & welfare of companion animals, improvement in livestock products, and prevention of transmission of diseases from animal to humans. Humans are largely dependent on animals, as they are the major source of milk, meat, and other dairy products. Thus, the demand for animal products also increases with rise in population, fueling the production of vaccines for cattle, pigs, poultry, and sheep. The global animal vaccines market generated revenue of $7,571 in 2017, and is estimated to reach $11,885 million by 2025, registering a CAGR of 5.7% from 2018 to 2025.
The animal vaccines market is segmented on the basis of product type, animal type, and geography. By product type, the market is categorized into attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. Based on animal type, it is classified into companion animals, cattle, pigs, poultry, and sheep. The companion animals segment is subsegmented into dogs, cats, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The animal vaccines market is growing at a steady pace due to increase in pet ownership in developed countries and rise in number of cattle & poultry in developing countries. Furthermore, rise in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the market growth. Moreover, rise in demand for animal vaccines has led to the emergence of multiple new vaccines However, lack of animal health awareness and possibility of adverse impact on veterinary vaccines on human and other animal health can restrain the growth for animal vaccines market. Furthermore, the advanced in vaccine products and production of animal vaccines for hybrid animals can help open new avenues for the growth of the animal vaccines market.
KEY BENEFITS
o Inactivated Vaccines
o Subunit Vaccines
o Toxoid Vaccines
o Conjugate Vaccines
o Recombinant Vaccines
o DNA Vaccines
o Fish
o Pigs
o Poultry
o Sheep
The animal vaccines market is segmented on the basis of product type, animal type, and geography. By product type, the market is categorized into attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. Based on animal type, it is classified into companion animals, cattle, pigs, poultry, and sheep. The companion animals segment is subsegmented into dogs, cats, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The animal vaccines market is growing at a steady pace due to increase in pet ownership in developed countries and rise in number of cattle & poultry in developing countries. Furthermore, rise in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the market growth. Moreover, rise in demand for animal vaccines has led to the emergence of multiple new vaccines However, lack of animal health awareness and possibility of adverse impact on veterinary vaccines on human and other animal health can restrain the growth for animal vaccines market. Furthermore, the advanced in vaccine products and production of animal vaccines for hybrid animals can help open new avenues for the growth of the animal vaccines market.
KEY BENEFITS
- The global animal vaccines market report provides an extensive analysis of the current market trends and future estimations prevailing in the market.
- The market estimations from 2018 to 2025 are based on high-end analysis of the key developments.
- The market scenario is comprehensively analyzed with respect to the product type and animal type.
- Recent developments and key manufacturers are listed and analyzed to understand the competitive market scenario.
- In-depth geographical analysis helps understand the regional market, which assists in strategic business planning.
- By Product
o Inactivated Vaccines
o Subunit Vaccines
o Toxoid Vaccines
o Conjugate Vaccines
o Recombinant Vaccines
o DNA Vaccines
- By Animal Type
- Dogs
- Cats
- Others
o Fish
o Pigs
o Poultry
o Sheep
- By Region
- U.S.
- Canada
- Mexico
- Germany
- UK
- France
- Italy
- Rest of Europe
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
- Brazil
- Turkey
- Venezuela
- Saudi Arabia
- Rest of LAMEA
- Bayer AG
- Eli Lilly and Company
- Boehringer
- Ingelheim GmbH
- Merck & Co., Inc.
- Zoetis Inc.
- Ceva Santé Animale
- Sanofi S.A.
- Nutreco N.V.
- Virbac S.A.
- Nexvet
- PHL Associates, Inc.
- Hygieia Biological Laboratories
- Colorado Serum Company
- Pfizer
- Arko Laboratories, Ltd.
Note: Product cover images may vary from those shown
2 of 4
Chapter 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top winning strategies
3.2.2. Top investment pockets
3.3. Government Regulations
3.3.1. Center for Veterinary Biologics (CVB)
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growth in demand for pet insurance
3.4.1.2. Increase in prevalence of animal diseases
3.4.1.3. Growth in ownership of companion animal
3.4.1.4. Rise in animal health expenditure
3.4.2. Restraints
3.4.2.1. Highly competitive meat and milk prices
3.4.2.2. Adverse impact of veterinary vaccines on human and animal health
3.4.3. Opportunities
3.4.3.1. Advancement in vaccine products
3.4.3.2. Increase in demand for hybrid animals
Chapter 4: ANIMAL VACCINES MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Attenuated Vaccines
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Market analysis, by country
4.3. Inactivated Vaccines
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Market analysis, by country
4.4. Subunit Vaccines
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Market analysis, by country
4.5. Toxoid Vaccines
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Market analysis, by country
4.6. Conjugate Vaccines
4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
4.6.4. Market analysis, by country
4.7. Recombinant Vaccines
4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Market analysis, by country
4.8. DNA Vaccines
4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast
4.8.4. Market analysis, by country
Chapter 5: ANIMAL VACCINES MARKET, BY ANIMAL TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Companion animal
5.2.1. Market size and forecast, by type
5.2.1.1. Dogs
5.2.1.2. Cats
5.2.1.3. Other Companion animal vaccines segment
5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country
5.3. Cattle
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Pigs
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Poultry
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Sheep
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
Chapter 6: ANIMAL VACCINES MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast, by product
6.2.4. Market size and forecast, by animal
6.2.5. Market size and forecast, by country
6.2.5.1. U.S. market size and forecast, by product
6.2.5.2. U.S. market size and forecast, by animal
6.2.5.3. Canada market size and forecast, by product
6.2.5.4. Canada market size and forecast, by animal
6.2.5.5. Mexico market size and forecast, by product
6.2.5.6. Mexico market size and forecast, by animal
6.3. Europe
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast, by product
6.3.4. Market size and forecast, by animal
6.3.5. Market size and forecast, by country
6.3.5.1. Germany market size and forecast, by product
6.3.5.2. Germany market size and forecast, by animal
6.3.5.3. France market size and forecast, by product
6.3.5.4. France market size and forecast, by animal
6.3.5.5. UK market size and forecast, by product
6.3.5.6. UK market size and forecast, by animal
6.3.5.7. Italy market size and forecast, by product
6.3.5.8. Italy market size and forecast, by animal
6.3.5.9. Rest of Europe market size and forecast, by product
6.3.5.10. Rest of Europe market size and forecast, by animal
6.4. Asia-Pacific
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast, by product
6.4.4. Market size and forecast, by animal
6.4.5. Market size and forecast, by country
6.4.5.1. Japan market size and forecast, by product
6.4.5.2. Japan market size and forecast, by animal
6.4.5.3. China market size and forecast, by product
6.4.5.4. China market size and forecast, by animal
6.4.5.5. Australia market size and forecast, by product
6.4.5.6. Australia market size and forecast, by animal
6.4.5.7. India market size and forecast, by product
6.4.5.8. India market size and forecast, by animal
6.4.5.9. South Korea market size and forecast, by product
6.4.5.10. South Korea market size and forecast, by animal
6.4.5.11. Rest of Asia-Pacific market size and forecast, by product
6.4.5.12. Rest of Asia-Pacific market size and forecast, by animal
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast, by product
6.5.4. Market size and forecast, by animal
6.5.5. Market size and forecast, by country
6.5.5.1. Brazil market size and forecast, by product
6.5.5.2. Brazil market size and forecast, by animal
6.5.5.3. Saudi Arabia market size and forecast, by product
6.5.5.4. Saudi Arabia market size and forecast, by animal
6.5.5.5. Rest of LAMEA market size and forecast, by product
6.5.5.6. Rest of LAMEA market size and forecast, by animal
Chapter 7: COMPANY PROFILES
7.1. Anicon Labor GmbH
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.2. Boehringer Ingelheim GmbH
7.2.1. Company overview
7.2.2. Operating business segments
7.2.3. Business performance
7.3. Ceva Sant Animale
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.3.4. Business performance
7.3.5. Key strategic moves & developments, 2014-2016
7.4. Hygieia Biological Laboratories
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.5. Merck & company Inc.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Romvac company S.A.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.7. Sanofi S.A.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Vaxxinova Gmbh-Germany
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Key strategic moves and developments
7.9. Virbac S.A
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. Zoetis Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves & developments, 2015-2017
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top winning strategies
3.2.2. Top investment pockets
3.3. Government Regulations
3.3.1. Center for Veterinary Biologics (CVB)
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growth in demand for pet insurance
3.4.1.2. Increase in prevalence of animal diseases
3.4.1.3. Growth in ownership of companion animal
3.4.1.4. Rise in animal health expenditure
3.4.2. Restraints
3.4.2.1. Highly competitive meat and milk prices
3.4.2.2. Adverse impact of veterinary vaccines on human and animal health
3.4.3. Opportunities
3.4.3.1. Advancement in vaccine products
3.4.3.2. Increase in demand for hybrid animals
Chapter 4: ANIMAL VACCINES MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Attenuated Vaccines
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Market analysis, by country
4.3. Inactivated Vaccines
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Market analysis, by country
4.4. Subunit Vaccines
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Market analysis, by country
4.5. Toxoid Vaccines
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Market analysis, by country
4.6. Conjugate Vaccines
4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
4.6.4. Market analysis, by country
4.7. Recombinant Vaccines
4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Market analysis, by country
4.8. DNA Vaccines
4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast
4.8.4. Market analysis, by country
Chapter 5: ANIMAL VACCINES MARKET, BY ANIMAL TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Companion animal
5.2.1. Market size and forecast, by type
5.2.1.1. Dogs
5.2.1.2. Cats
5.2.1.3. Other Companion animal vaccines segment
5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country
5.3. Cattle
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Pigs
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Poultry
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Sheep
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
Chapter 6: ANIMAL VACCINES MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast, by product
6.2.4. Market size and forecast, by animal
6.2.5. Market size and forecast, by country
6.2.5.1. U.S. market size and forecast, by product
6.2.5.2. U.S. market size and forecast, by animal
6.2.5.3. Canada market size and forecast, by product
6.2.5.4. Canada market size and forecast, by animal
6.2.5.5. Mexico market size and forecast, by product
6.2.5.6. Mexico market size and forecast, by animal
6.3. Europe
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast, by product
6.3.4. Market size and forecast, by animal
6.3.5. Market size and forecast, by country
6.3.5.1. Germany market size and forecast, by product
6.3.5.2. Germany market size and forecast, by animal
6.3.5.3. France market size and forecast, by product
6.3.5.4. France market size and forecast, by animal
6.3.5.5. UK market size and forecast, by product
6.3.5.6. UK market size and forecast, by animal
6.3.5.7. Italy market size and forecast, by product
6.3.5.8. Italy market size and forecast, by animal
6.3.5.9. Rest of Europe market size and forecast, by product
6.3.5.10. Rest of Europe market size and forecast, by animal
6.4. Asia-Pacific
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast, by product
6.4.4. Market size and forecast, by animal
6.4.5. Market size and forecast, by country
6.4.5.1. Japan market size and forecast, by product
6.4.5.2. Japan market size and forecast, by animal
6.4.5.3. China market size and forecast, by product
6.4.5.4. China market size and forecast, by animal
6.4.5.5. Australia market size and forecast, by product
6.4.5.6. Australia market size and forecast, by animal
6.4.5.7. India market size and forecast, by product
6.4.5.8. India market size and forecast, by animal
6.4.5.9. South Korea market size and forecast, by product
6.4.5.10. South Korea market size and forecast, by animal
6.4.5.11. Rest of Asia-Pacific market size and forecast, by product
6.4.5.12. Rest of Asia-Pacific market size and forecast, by animal
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast, by product
6.5.4. Market size and forecast, by animal
6.5.5. Market size and forecast, by country
6.5.5.1. Brazil market size and forecast, by product
6.5.5.2. Brazil market size and forecast, by animal
6.5.5.3. Saudi Arabia market size and forecast, by product
6.5.5.4. Saudi Arabia market size and forecast, by animal
6.5.5.5. Rest of LAMEA market size and forecast, by product
6.5.5.6. Rest of LAMEA market size and forecast, by animal
Chapter 7: COMPANY PROFILES
7.1. Anicon Labor GmbH
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.2. Boehringer Ingelheim GmbH
7.2.1. Company overview
7.2.2. Operating business segments
7.2.3. Business performance
7.3. Ceva Sant Animale
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.3.4. Business performance
7.3.5. Key strategic moves & developments, 2014-2016
7.4. Hygieia Biological Laboratories
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.5. Merck & company Inc.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Romvac company S.A.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.7. Sanofi S.A.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Vaxxinova Gmbh-Germany
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Key strategic moves and developments
7.9. Virbac S.A
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. Zoetis Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves & developments, 2015-2017
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
According to this report titled, 'Animal Vaccines Market by Product Type and Animal Type: Global Opportunity Analysis and Industry Forecast, 2018 - 2025',the global animal vaccines market accounted for $8,059 in 2017, and is estimated to reach $12,845 million by 2025, registering a CAGR of 5.9% from 2018 to 2025.
Animal vaccines are essential to ensure better animal health and welfare. Various vaccines such as attenuated vaccines, subunit vaccines, toxoid vaccines, and DNA vaccines help provide protection against multiple diseases, including rabies and foot & mouth disease. These vaccines offer cost-effective solutions instead of excessive antibiotic administration to treat such diseases.
Increase in adoption of companion animals in the developing countries is the major factor that drives the growth of this market. The market has witnessed moderate growth in recent years due to emerging diseases that affect livestock. The outbreak of epidemics results in severe mass wipeouts of animals, and is a growing concern for the industries dependent on products obtained through farm animals. Moreover, zoonotic diseases that affect animals pose a threat to the public health, hence avoiding transmission of such diseases via vaccination is a significant factor in disease management.
Based on animal type, the animal vaccines market is classified into companion animals, cattle, pigs, poultry, and sheep. The companion animals segment is subsegmented into dogs, cats, and others. Cattle segment generated maximum revenue in 2017 attributable to increase in consumption of meat, milk, and dairy products, making sustainable animal health a vital aspect in disease management. However, the companion animal segment is anticipated to grow at a faster pace during the forecast period.
By product type, the animal vaccines market is categorized into attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. Attenuated vaccines segment dominated the product type segment with maximum share in 2017. Attenuated vaccines can provide stronger immunity as compared to other vaccines, which positively contributes toward the market growth. However, DNA vaccines is expected to be the fastest growing segment.
In 2017, North America accounted for the highest revenue in the global animal vaccines market. Asia-Pacific is expected to show highest growth rate. Rise in disposable income, increase in animal healthcare expenditure, and surge in adoption of companion animals are the major factors that drive the growth of animal vaccines market in Asia-Pacific.
Key Findings of the Animal Vaccines Market:
DNA vaccines segment is projected to grow fastest during the analysis period.
Cattle vaccines generates highest revenue, and is expected to continue its dominance during the forecast period.
North America dominated the global animal vaccines market, and projected to grow at a CAGR of 5.3%.
China is expected to grow at the highest CAGR of 7.7% in Asia-Pacific.
The companion animal segment exhibits fast-paced growth rate, registering a CAGR of 6.4%.
The report provides a comprehensive analysis of the key players operating in the global animal vaccines market. These players include Merck & Co., Inc., Zoetis Inc., Ceva Sant Animale, Sanofi S.A., Romvac, Vaxxinova, Biovac, Merial, and Anicon Labor GmbH.
The other players operating in the global animal vaccines market include Nexvet, PHL Associates, Inc., Hygieia Biological Laboratories, Colorado Serum Company, Pfizer, and Arko Laboratories, Ltd.
Animal vaccines are essential to ensure better animal health and welfare. Various vaccines such as attenuated vaccines, subunit vaccines, toxoid vaccines, and DNA vaccines help provide protection against multiple diseases, including rabies and foot & mouth disease. These vaccines offer cost-effective solutions instead of excessive antibiotic administration to treat such diseases.
Increase in adoption of companion animals in the developing countries is the major factor that drives the growth of this market. The market has witnessed moderate growth in recent years due to emerging diseases that affect livestock. The outbreak of epidemics results in severe mass wipeouts of animals, and is a growing concern for the industries dependent on products obtained through farm animals. Moreover, zoonotic diseases that affect animals pose a threat to the public health, hence avoiding transmission of such diseases via vaccination is a significant factor in disease management.
Based on animal type, the animal vaccines market is classified into companion animals, cattle, pigs, poultry, and sheep. The companion animals segment is subsegmented into dogs, cats, and others. Cattle segment generated maximum revenue in 2017 attributable to increase in consumption of meat, milk, and dairy products, making sustainable animal health a vital aspect in disease management. However, the companion animal segment is anticipated to grow at a faster pace during the forecast period.
By product type, the animal vaccines market is categorized into attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. Attenuated vaccines segment dominated the product type segment with maximum share in 2017. Attenuated vaccines can provide stronger immunity as compared to other vaccines, which positively contributes toward the market growth. However, DNA vaccines is expected to be the fastest growing segment.
In 2017, North America accounted for the highest revenue in the global animal vaccines market. Asia-Pacific is expected to show highest growth rate. Rise in disposable income, increase in animal healthcare expenditure, and surge in adoption of companion animals are the major factors that drive the growth of animal vaccines market in Asia-Pacific.
Key Findings of the Animal Vaccines Market:
DNA vaccines segment is projected to grow fastest during the analysis period.
Cattle vaccines generates highest revenue, and is expected to continue its dominance during the forecast period.
North America dominated the global animal vaccines market, and projected to grow at a CAGR of 5.3%.
China is expected to grow at the highest CAGR of 7.7% in Asia-Pacific.
The companion animal segment exhibits fast-paced growth rate, registering a CAGR of 6.4%.
The report provides a comprehensive analysis of the key players operating in the global animal vaccines market. These players include Merck & Co., Inc., Zoetis Inc., Ceva Sant Animale, Sanofi S.A., Romvac, Vaxxinova, Biovac, Merial, and Anicon Labor GmbH.
The other players operating in the global animal vaccines market include Nexvet, PHL Associates, Inc., Hygieia Biological Laboratories, Colorado Serum Company, Pfizer, and Arko Laboratories, Ltd.
Note: Product cover images may vary from those shown
5 of 4
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
